Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Membrane immunoglobulin M (mIgM), also known as the B cell antigen receptor (BCR), is the monomeric form of IgM expressed on the surface of naïve and immature B lymphocytes. It consists of two μ heavy chains (each with four constant domains: Cμ1-Cμ4, plus a transmembrane tailpiece) and two light chains (kappa or lambda), linked by disulfide bonds and non-covalent interactions. The μ heavy chain has an additional hydrophobic transmembrane domain (about 41 amino acids) for anchoring to the B cell membrane. As a BCR, mIgM recognizes antigens with high specificity via its variable domains, initiating B cell signaling, activation, proliferation, and differentiation into plasma cells or memory B cells. It plays a key role in primary immune responses, self/non-self discrimination, and B cell development. Unlike secreted pentameric IgM (sIgM), mIgM does not incorporate a J-chain and functions primarily in antigen detection rather than secretion or mucosal transport.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane immunoglobulin M (mIgM) (mIgM).